Posted by Michael Wonder on 25 Oct 2021
Alkermes receives FDA fast track designation for nemvaleukin alfa in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer
26 October 2021 - Second fast track designation for nemvaleukin.
Alkermes today announced that the U.S. FDA has granted fast track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 variant immunotherapy, in combination with pembrolizumab, an anti-PD-1 antibody, for the treatment of platinum-resistant ovarian cancer.
